Preventive Therapy for Tuberculosis in HIV Infected Persons
Title: Evaluation of efficacy of two different preventive therapy regimens for tuberculosis in HIV infected persons
Phase: Phase III trial
Population: 650 HIV positive patients without tuberculosis
Number of sites: Three
- Tuberculosis Research centre, Chennai
- Government General Hospital, Chennai
- Government Rajaji Hospital, Madurai
Study Duration: 36 months
Study Objectives: To compare the efficacy of two TB preventive therapy regimens in reducing the incidence of tuberculosis and mortality among HIV-infected persons
The study will be a two-armed prospective randomized clinical trial among HIV- positive patients without active tuberculosis. Enrolled patients will be assigned to one of the two unsupervised self-administered treatment regimens i.e. EH for 6 months or INH alone for 3 years. At the end of a 3-year follow-up, incidence of TB and overall mortality will be compared in each group.
Study Endpoints:The primary end point of the study will be development of tuberculosis and the secondary endpoints will include adverse drug reactions and mortality rate.
|Human Immunodeficiency Virus Tuberculosis||Drug: Isoniazid with Ethambutol||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons|
- Primary outcome measure is the development of tuberculosis. [ Time Frame: September 2008 ]
- Secondary outcome measures include adverse drug reactions and mortality rate. [ Time Frame: September 2008 ]
|Study Start Date:||February 2001|
|Study Completion Date:||June 2011|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
Active Comparator: Isoniazid
Isoniazid (300mg) daily for 36 months
Drug: Isoniazid with Ethambutol
Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
Study population and enrollment:
All HIV positive patients seeking care at one of the study centers, above the age of 15 years, not suffering from a serious illness, non-pregnant, and in whom TB was ruled out using the enhanced screening process, will be enrolled in the study. The consent form for prophylaxis trial will be read to the patients in the local language and written consent will be obtained from willing patients
Randomization and Dosing:
All patients enrolled in the prevention trial will be randomized to one of the study groups using a permuted block randomization scheme of four. Stratification will be done by Mantoux reading (>5mm and ≤5mm). The group assignment list will be generated centrally before the start of trial and sequentially numbered sealed envelopes containing the study group assigned will be prepared independently. At the initiation of prophylaxis, each patient will be counseled about the importance of taking drugs regularly. Patients will be asked to return the empty packets as well as unused tablets at each monthly visit.
The treatment regimens in each study group will be as follows:
- Ethambutol (800 mg) and Isoniazid (300 mg) daily for six months, self-administered, collected once in fifteen days.
- Isoniazid (300 mg) daily for 3 years with fortnightly collection of drugs Subjects in both study groups will receive 10 mg of Pyridoxine daily during treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00351702
|Tuberculosis Research Centre|
|Chennai, Tamilnadu, India, 600 031|
|Principal Investigator:||Soumya Swaminathan, MD MNAMS||Tuberculosis Research Centre, India|